MCID: PRS030
MIFTS: 49

Persistent Fetal Circulation Syndrome

Categories: Cardiovascular diseases, Fetal diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Persistent Fetal Circulation Syndrome

MalaCards integrated aliases for Persistent Fetal Circulation Syndrome:

Name: Persistent Fetal Circulation Syndrome 11 28 43 14 16 71 33
Persistent Fetal Circulation 11 75 31 33
Fetal Circulation 11 14 33
Persistent Pulmonary Hypertension of the Newborn 11 33
Congenital Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins 11
Pphn - [persistent Pulmonary Hypertension of the Newborn] 33
Pfc - [persistent Fetal Circulation] Syndrome 33
Primary Pulmonary Hypertension of Newborn 33
Persistent Foetal Circulation Syndrome 11
Newborn Pulmonary Hypertension 33
Persistent Foetal Circulation 11

Classifications:



External Ids:

Disease Ontology 11 DOID:13042
ICD9CM 34 747.83
MeSH 43 D010547
NCIt 49 C85006
SNOMED-CT 68 35604006
ICD10 31 P29.3
ICD11 33 346808536
UMLS 71 C0031190

Summaries for Persistent Fetal Circulation Syndrome

MalaCards based summary: Persistent Fetal Circulation Syndrome, also known as persistent fetal circulation, is related to congestive heart failure and placental insufficiency. An important gene associated with Persistent Fetal Circulation Syndrome is MIR517A (MicroRNA 517a), and among its related pathways/superpathways are Signal Transduction and Peptide hormone metabolism. The drugs Adenosine and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include heart, placenta and brain, and related phenotypes are homeostasis/metabolism and renal/urinary system

Wikipedia: 75 Persistent fetal circulation is a condition caused by a failure in the systemic circulation and... more...

Related Diseases for Persistent Fetal Circulation Syndrome

Diseases related to Persistent Fetal Circulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 30.9 PDE5A INS IL6 EDN1 ALB
2 placental insufficiency 30.8 PGF LEP IL6
3 hypokalemia 30.8 POMC INS HSD11B2 ALB
4 cerebral palsy 30.8 OXT NOS3 LEP IL6 IGF1 ALB
5 eclampsia 30.8 PGF OXT NOS3 IL6 EDN1 ALB
6 graves disease 1 30.7 POMC INS ALB
7 tricuspid valve insufficiency 30.7 PDE5A EDN1 ALB
8 urinary tract infection 30.7 INS IL6 ALB
9 aspiration pneumonia 30.6 POMC INS IL6 ALB
10 asphyxia neonatorum 30.6 OXT INS IL6 ALB
11 severe pre-eclampsia 30.5 PGF OXT MIR517A LEP
12 interstitial lung disease 30.5 MIR21 IL6 IGF1 EDN1
13 beta-thalassemia 30.5 LEP INS IL6 IGF1
14 preterm premature rupture of the membranes 30.5 PGF OXT IL6
15 meconium aspiration syndrome 30.5 PDE5A OXT IL6 EDN1
16 stroke, ischemic 30.4 NOS3 MIR21 INS IL6 ALB
17 attention deficit-hyperactivity disorder 30.4 POMC OXT LEP INS IL6
18 ischemia 30.4 PGF PDE5A NOS3 MIR21 IL6 EDN1
19 oligohydramnios 30.4 PGF OXT MIR517A EDN1 ALB
20 hypoglycemia 30.3 POMC OXT LEP INS IGF1 ALB
21 respiratory failure 30.3 MIR21 INS IL6 ALB
22 inherited metabolic disorder 30.3 MIR21 LEP INS IL6 IGF1 ALB
23 hellp syndrome 30.3 PGF LEP IL6 HSD11B2 EDN1
24 pre-eclampsia 30.3 PGF PDE5A OXT NOS3 LEP INS
25 vascular disease 30.2 PDE5A NOS3 MIR21 LEP INS IL6
26 placental abruption 30.2 PGF OXT MIR517A
27 pulmonary hypertension 30.2 PGF PDE5A NOS3 MIR21 IL6 EDN1
28 hypertrophic cardiomyopathy 30.2 NOS3 MIR21 INS IL6 IGF1 EDN1
29 aspiration pneumonitis 30.2 OXT IL6 ALB
30 choriocarcinoma 30.2 PGF HSD11B2 CSH2 CSH1
31 gestational diabetes 30.1 PGF NOS3 LEP INS IL6 IGF1
32 patent ductus arteriosus 1 30.1 PDE5A INS IL6 IGF1 EDN1 ALB
33 polyhydramnios 30.1 OXT INS EDN1
34 leptin deficiency or dysfunction 30.1 POMC OXT LEP INS IL6 IGF1
35 patent foramen ovale 30.0 PDE5A INS IL6 EDN1 ALB
36 deficiency anemia 30.0 OXT LEP INS IL6 IGF1 ALB
37 arteriosclerosis 30.0 MIR21 INS IL6 EDN1
38 hyperinsulinism 30.0 LEP INS IGF1 EDN1
39 pain agnosia 30.0 POMC OXT INS IL6 ALB
40 type 1 diabetes mellitus 29.9 LEP INS IL6 IGF1 HSD11B2 ALB
41 skin disease 29.7 POMC MIR21 INS IL6 IGF1 ALB
42 anxiety 29.7 POMC OXT LEP INS IL6 IGF1
43 lipoprotein quantitative trait locus 29.7 PGF PDE5A NOS3 MIR21 INS IL6
44 heart disease 29.7 PGF PDE5A NOS3 MIR21 INS IL6
45 chronic kidney disease 29.6 NOS3 MIR21 LEP INS IL6 IGF1
46 type 2 diabetes mellitus 29.2 POMC PGF PDE5A NOS3 MIR21 LEP
47 diabetes mellitus 29.2 POMC PGF PDE5A OXT NOS3 MIR21
48 hypertension, essential 28.8 SLC1A7 POMC PGF PDE5A OXT NOS3
49 alveolar capillary dysplasia with misalignment of pulmonary veins 11.4
50 testicular trophoblastic tumor 10.5 CSH2 CSH1

Graphical network of the top 20 diseases related to Persistent Fetal Circulation Syndrome:



Diseases related to Persistent Fetal Circulation Syndrome

Symptoms & Phenotypes for Persistent Fetal Circulation Syndrome

MGI Mouse Phenotypes related to Persistent Fetal Circulation Syndrome:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ALB CSH1 CSH2 EDN1 FCGRT HSD11B2
2 renal/urinary system MP:0005367 10.29 ALB CSH1 CSH2 EDN1 HSD11B2 IGF1
3 growth/size/body region MP:0005378 10.25 CSH1 CSH2 EDN1 IGF1 IL6 INS
4 adipose tissue MP:0005375 10.16 CSH1 CSH2 IGF1 IL6 INS LEP
5 liver/biliary system MP:0005370 10.13 ALB CSH1 CSH2 IL6 INS LEP
6 endocrine/exocrine gland MP:0005379 10.11 ALB CSH1 CSH2 EDN1 IGF1 IL6
7 muscle MP:0005369 10.1 ALB EDN1 HSD11B2 IGF1 IL6 INS
8 neoplasm MP:0002006 10.07 ALB HSD11B2 IGF1 IL6 LEP PGF
9 cardiovascular system MP:0005385 10.07 ALB CSH1 CSH2 EDN1 HSD11B2 IGF1
10 digestive/alimentary MP:0005381 9.97 ALB EDN1 HSD11B2 IL6 INS LEP
11 immune system MP:0005387 9.93 ALB CSH1 CSH2 FCGRT IGF1 IL6
12 respiratory system MP:0005388 9.56 CSH1 CSH2 IGF1 IL6 LEP NOS3
13 mortality/aging MP:0010768 9.5 ALB CSH1 CSH2 EDN1 FCGRT HSD11B2

Drugs & Therapeutics for Persistent Fetal Circulation Syndrome

Drugs for Persistent Fetal Circulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4 58-61-7 60961
2 Pharmaceutical Solutions Phase 4
3
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
5
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
6
Sildenafil Approved, Investigational Phase 3 139755-83-2, 171599-83-0 5212 135398744
7
Racephedrine Approved, Experimental Phase 2, Phase 3 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
8
Phenylephrine Approved Phase 2, Phase 3 59-42-7 6041
9
Oxymetazoline Approved, Investigational Phase 2, Phase 3 1491-59-4 4636
10
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
12 Cardiotonic Agents Phase 2, Phase 3
13 Phosphodiesterase Inhibitors Phase 3
14 Phosphodiesterase 5 Inhibitors Phase 3
15 Citrate Phase 3
16 Central Nervous System Stimulants Phase 2, Phase 3
17 Adrenergic alpha-Agonists Phase 2, Phase 3
18 Adrenergic Agonists Phase 2, Phase 3
19 Adrenergic Agents Phase 2, Phase 3
20 Vasoconstrictor Agents Phase 2, Phase 3
21 Mydriatics Phase 2, Phase 3
22 Sympathomimetics Phase 2, Phase 3
23 Nasal Decongestants Phase 2, Phase 3
24 Antihypertensive Agents Phase 3
25 Endothelin Receptor Antagonists Phase 3
26
Magnesium sulfate Approved, Investigational, Vet_approved Phase 1, Phase 2 7487-88-9
27
Epoprostenol Approved Phase 2 61849-14-7, 35121-78-9 5282411
28
Treprostinil Approved, Investigational Phase 2 81846-19-7 6918140
29
Tezosentan Investigational Phase 2 180384-57-0
30 Hormones Phase 1, Phase 2
31 Anti-Arrhythmia Agents Phase 1, Phase 2
32 Calcium, Dietary Phase 1, Phase 2
33 Anticonvulsants Phase 1, Phase 2
34 Anesthetics Phase 1, Phase 2
35 calcium channel blockers Phase 1, Phase 2
36 Analgesics Phase 1, Phase 2
37 Tocolytic Agents Phase 1, Phase 2
38 Antidepressive Agents, Tricyclic Phase 2
39
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
40
Metaraminol Approved, Investigational 54-49-9 5906
41
Carbon monoxide Approved, Investigational 630-08-0 281
42
Tadalafil Approved, Investigational 171596-29-5 110635
43
Milrinone Approved 78415-72-2 4197
44 Immunoglobulins
45 Antibodies
46 Liver Extracts
47 Phosphodiesterase 3 Inhibitors
48 Natriuretic Peptide, Brain

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation Completed NCT00732537 Phase 4 inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
2 Oral Sildenafil in Persistent Pulmonary Hypertension of Neonates Secondary to Meconium Aspiration Syndrome: A Randomized Placebo Controlled Trial Completed NCT01757782 Phase 4 Oral Sildenafil;Placebo (distilled water)
3 Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure Withdrawn NCT01891500 Phase 4 Inhaled nitric oxide;Nitrogen Gas;Crossover iNO
4 Early Combined Use of Inhaled Nitric Oxide and Oral Sildenafil on the Outcome of Pulmonary Hypertension in New Born Infants Unknown status NCT01558466 Phase 3 Sildenafil;diluent
5 A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT Completed NCT01720524 Phase 3 placebo;iv sildenafil
6 Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study Completed NCT03047109 Phase 2, Phase 3 Phenylephrine;Ephedrine
7 The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure Terminated NCT00005776 Phase 3 Inhaled nitric oxide;Placebo
8 Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure Terminated NCT00005773 Phase 3 Inhaled Nitric Oxide;Standard iNO therapy
9 Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN) Terminated NCT01389856 Phase 3 Bosentan;Matching placebo
10 Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn Completed NCT04328636 Phase 1, Phase 2 Nebulized Magnesium Sulfate;Intravenous Magnesium Sulfate
11 Milrinone in Congenital Diaphragmatic Hernia Recruiting NCT02951130 Phase 2 Milrinone;Placebo (5% Dextrose)
12 Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study Recruiting NCT02261883 Phase 2 IV Remodulin;Placebo
13 Effectiveness of Nebulized Magnesium Sulfate Combined With Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn Recruiting NCT04898114 Phase 1, Phase 2 Magnesium sulfate;Sildenafil Citrate
14 A Single Arm Single Centre Study To Investigate Safety And Efficacy Of Sildenafil In Near Term And Term Newborns With Persistent Pulmonary Hypertension Of The Newborn (PPHN) Terminated NCT01069861 Phase 2 sildanefil
15 A Randomized, Double Blind, Placebo-controlled Pilot Study of the Safety and Effective Dosing of Inhaled Iloprost in Pediatric Patients With Pulmonary Hypertension Treated With Inhaled Nitric Oxide Withdrawn NCT00981591 Phase 1, Phase 2 Iloprost;Placebo
16 An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN) Withdrawn NCT01360671 Phase 2 Sildenafil
17 Pharmacokinetics of Sildenafil in Premature Infants Completed NCT01670136 Phase 1 1 dose of sildenafil
18 Doppler Ultrasonographic Assessment of Fetal Internal Thoracic Artery Indexes Unknown status NCT04686240
19 Examination of Perfusion Index in Term and Preterm Newborns Through Plethismography Unknown status NCT02380040
20 Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension Unknown status NCT01373749 NO inhalation;NO inhalation continued with sildenafil
21 Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean Unknown status NCT02245191 Ephedrine;Phenylephrine;Metaraminol
22 NO Need to Ventilate: A Trial of Non-invasive iNO in Persistent Pulmonary Hypertension of the Newborn Completed NCT00139217 iNO
23 Risk Factors for Pulmonary Hypertension of the Newborn Completed NCT00005497
24 NEURodevelopmental Outcome in Children Between One and Five Years After Persistent Pulmonary Hypertension Of the Newborn Completed NCT04841070
25 Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO) Completed NCT00371241
26 Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children Completed NCT00005323
27 Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study Completed NCT01203423
28 A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO Completed NCT02940327
29 Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN) Recruiting NCT00710177
30 Assessment of Effects of Maternal Smoking on Fetal Liver Circulation With Ultrasonography Active, not recruiting NCT04721782
31 Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension (POST-IT) Enrolling by invitation NCT04938167
32 Population Pharmacokinetics and Dosage Individualization of Bosentan, Sildenafil and Tadalafil in Persistent Pulmonary Hypertension of the Newborn Not yet recruiting NCT04379180 Bosentan Tablets;Sildenafil Tablet;Tadalafil Tablets
33 Clinical Significance of N-Terminal Pro-Brain Natriuretic Peptide Levels in Persistent Pulmonary Hypertension Terminated NCT00443859
34 Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention Terminated NCT01088997 Milrinone Lactate

Search NIH Clinical Center for Persistent Fetal Circulation Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: persistent fetal circulation syndrome

Genetic Tests for Persistent Fetal Circulation Syndrome

Genetic tests related to Persistent Fetal Circulation Syndrome:

# Genetic test Affiliating Genes
1 Persistent Fetal Circulation Syndrome 28

Anatomical Context for Persistent Fetal Circulation Syndrome

Organs/tissues related to Persistent Fetal Circulation Syndrome:

MalaCards : Heart, Placenta, Brain, Fetal Liver, Liver, Lung, Endothelial

Publications for Persistent Fetal Circulation Syndrome

Articles related to Persistent Fetal Circulation Syndrome:

(show top 50) (show all 3376)
# Title Authors PMID Year
1
Ex vivo perfusion of the human placenta to investigate pregnancy pathologies. 62
36343527 2022
2
Maternal, neonatal and placental characteristics of SARS-CoV-2 positive mothers. 62
33645395 2022
3
Implications of placentation type on species-specific colostrum properties in mammals. 62
36048628 2022
4
Nalbuphine: a candidate for treatment of women overwhelmed with sudden, intense labor pain? 62
33899644 2022
5
Amniotic fluid index measurements in the second and third trimester and correlation to fetal biometric parameters - new reference based on a big retrospective data. 62
34470112 2022
6
Transfer of Zolpidem to Cord Blood and Breast Milk: A Case Series Evaluating Zolpidem Serum Levels and Outcomes in Birth and Suckling Infants. 62
36301249 2022
7
Fetal Development in Anatomical Preparations of Ruysch and the Meckels in Comparison. 62
36429620 2022
8
Nanoparticle-mediated transgene expression of insulin-like growth factor 1 in the growth restricted guinea pig placenta increases placenta nutrient transporter expression and fetal glucose concentrations. 62
36094907 2022
9
Experimental human placental models for studying uptake, transport and toxicity of micro- and nanoplastics. 62
36417947 2022
10
Thyroid hormones: Metabolism and transportation in the fetoplacental unit. 62
36208482 2022
11
Asymmetrical transport of thyroxine across human term placenta. 62
36416258 2022
12
Placental proteins with predicted roles in fetal development decrease in premature infants. 62
35132128 2022
13
The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1). 62
36385642 2022
14
Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial. 62
35881893 2022
15
Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons: an almost 5-year retrospective cohort study. 62
36335293 2022
16
Perinatal changes of right ventricle-pulmonary artery coupling and its value in predicting persistent pulmonary hypertension of the newborn. 62
35852214 2022
17
Transposition With Hypertrophic Cardiomyopathy and Persistent Pulmonary Hypertension of the Newborn. 62
35604788 2022
18
Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child. 62
36181572 2022
19
Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn. 62
33477175 2022
20
The Relationship Between Placental Pathology and Neurodevelopmental Outcomes in Complex Congenital Heart Disease. 62
36201029 2022
21
Impact of Changes in Early Respiratory Support Management on Respiratory Outcomes of Preterm Infants. 62
35764345 2022
22
Analgesia during Parturition in Domestic Animals: Perspectives and Controversies on Its Use. 62
36230426 2022
23
Sildenafil improves pulmonary vascular remodeling in a rat model of persistent pulmonary hypertension of the newborn. 62
36198097 2022
24
Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. 62
35352868 2022
25
Volumetric Fetal Flow Imaging With Magnetic Resonance Imaging. 62
35604966 2022
26
Maternal exposure to ambient black carbon particles and their presence in maternal and fetal circulation and organs: an analysis of two independent population-based observational studies. 62
36208643 2022
27
Fetal Myocardial Expression of GLUT1: Roles of BPA Exposure and Cord Blood Exosomes in a Rat Model. 62
36291063 2022
28
Maternal Delta-9-Tetrahydrocannabinol Exposure Induces Abnormalities of the Developing Heart in Mice. 62
36255470 2022
29
Is It Time to Redefine Fetal Decelerations in Cardiotocography? 62
36294689 2022
30
Relationship of ANGPTL6 With Neonatal Glucose Homeostasis and Fat Mass Is Disrupted in Gestational Diabetic Pregnancies. 62
35876300 2022
31
Iron transport across the human placenta is regulated by hepcidin. 62
33069164 2022
32
Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension. 62
35688685 2022
33
Persistent pulmonary hypertension of the newborn: Historical perspectives. 62
35181257 2022
34
The interplay between pressure, flow, and resistance in neonatal pulmonary hypertension. 62
35787350 2022
35
Impact of hypertensive disorders of pregnancy on respiratory outcomes in extremely and very preterm infants: A population-based study in Japan. 62
35750024 2022
36
Long term outcome of babies with pulmonary hypertension. 62
36031529 2022
37
Veno-arterial extracorporeal membrane oxygenation for treatment of persistent pulmonary hypertension of the newborn. 62
36028404 2022
38
Pulmonary hypertension in the newborn- etiology and pathogenesis. 62
35963740 2022
39
Pulmonary hypertension and oxidative stress: Where is the link? 62
35473693 2022
40
Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn. 62
35469712 2022
41
Hyperandrogenism diminishes maternal-fetal fatty acid transport by increasing FABP4-mediated placental lipid accumulation†. 62
35357467 2022
42
Ligamentum arteriosum: Muscular and contractile. 62
36054486 2022
43
Echocardiographic Features of the Ductus Arteriosus and the Foramen Ovale in a Hospital-Based Population of Neonatal Foals. 62
36077962 2022
44
Study protocol for a randomized trial on timely delivery versus expectant management in late preterm small for gestational age pregnancies with an abnormal umbilicocerebral ratio (UCR): the DRIGITAT study. 62
35915472 2022
45
Effects of prenatal opioid and alcohol exposures on immune and serotonin factors in human placenta. 62
35364108 2022
46
[Application of extracorporeal membrane oxygenation in the treatment of persistent pulmonary hypertension of the newborn]. 62
35894194 2022
47
Ductus arteriosus: more than just the patent ductus arteriosus. 62
35809133 2022
48
RE: Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of persistent pulmonary hypertension of the newborn (PPHN): A multicenter, randomized, placebo-controlled trial. 62
35447124 2022
49
Persistence of persistent pulmonary hypertension of the newborn: A case of de novo TBX4 variant. 62
35874850 2022
50
Possible association between a polymorphism of EPAS1 gene and persistent pulmonary hypertension of the newborn: a case-control study. 62
34678164 2022

Variations for Persistent Fetal Circulation Syndrome

Expression for Persistent Fetal Circulation Syndrome

Search GEO for disease gene expression data for Persistent Fetal Circulation Syndrome.

Pathways for Persistent Fetal Circulation Syndrome

Pathways related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 13.52 EDN1 IGF1 IL6 INS LEP NOS3
2
Show member pathways
12.01 POMC LEP INS IGF1
3
Show member pathways
11.97 PGF NOS3 INS IL6 IGF1 CSH2
4 11.79 INS IL6 IGF1 ALB
5 11.74 LEP INS IL6 IGF1
6 11.62 LEP IL6 IGF1
7
Show member pathways
11.59 NOS3 HSD11B2 EDN1
8 11.49 IL6 IGF1 EDN1
9 11.45 POMC OXT INS
10 11.43 LEP INS IL6 IGF1
11 11.31 INS IL6 IGF1
12 11.27 LEP INS IL6
13
Show member pathways
10.91 POMC LEP EDN1
14 10.66 PDE5A NOS3
15 10.43 POMC LEP INS

GO Terms for Persistent Fetal Circulation Syndrome

Cellular components related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.98 POMC PGF OXT LEP INS IL6
2 extracellular space GO:0005615 9.72 ALB CSH1 CSH2 EDN1 FCGRT IGF1

Biological processes related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.42 CSH1 CSH2 IGF1 IL6 INS LEP
2 positive regulation of cell population proliferation GO:0008284 10.15 PGF MIR21 LEP INS IL6 IGF1
3 glucose homeostasis GO:0042593 10.11 IL6 INS LEP POMC
4 positive regulation of protein kinase B signaling GO:0051897 10.07 MIR21 LEP INS IGF1
5 female pregnancy GO:0007565 10.06 HSD11B2 LEP OXT PGF
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.98 MIR21 LEP INS IGF1
7 positive regulation of mitotic nuclear division GO:0045840 9.97 INS IGF1 EDN1
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.96 MIR21 IGF1 EDN1
9 regulation of blood pressure GO:0008217 9.95 POMC NOS3 LEP EDN1
10 response to activity GO:0014823 9.92 EDN1 IL6 LEP OXT
11 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.89 IGF1 EDN1
12 bone mineralization involved in bone maturation GO:0035630 9.88 LEP IGF1
13 activation of protein kinase B activity GO:0032148 9.88 MIR21 INS IGF1
14 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.87 NOS3 EDN1
15 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.76 MIR21 IL6
16 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.76 LEP IL6 CSH2 CSH1
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.71 MIR21 IGF1
18 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.65 MIR21 IGF1 EDN1
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 LEP IL6 IGF1 CSH2 CSH1
20 positive regulation of cardiac muscle hypertrophy GO:0010613 9.17 PDE5A MIR21 IGF1 EDN1

Molecular functions related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.65 PGF IL6 IGF1 CSH2 CSH1
2 hormone activity GO:0005179 9.5 POMC OXT LEP INS IGF1 EDN1

Sources for Persistent Fetal Circulation Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....